4.7 Article

Biocatalytic remediation of pharmaceutically active micropollutants for environmental sustainability*

期刊

ENVIRONMENTAL POLLUTION
卷 293, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.envpol.2021.118582

关键词

Pharmaceutical compounds; White-rot fungi; Oxidoreductases; Biocatalyst engineering; Biodegradation; Wastewater treatment

资金

  1. Consejo Nacional de Ciencia y Tecnologia (CONACYT) Mexico [CVU: 735340]
  2. Universiti Malaysia Terengganu [UMT/CRIM/2-2/2/23 (23), 55302]
  3. HICoE AKUATROP Trust [UMT/CRIM/2-2/5 Jilid 2 (10), 56051]

向作者/读者索取更多资源

This review discusses the technical and scientific progress of using oxidoreductase enzyme-based biocatalytic systems to remediate pharmaceutical compounds in water and wastewater. Immobilized biocatalysts have shown effectiveness in mitigating environmental pollution and enhancing biodegradation, but further research is needed on enzyme degradation mechanisms and toxicity monitoring.
The discharge of an alarming number of recalcitrant pollutants from various industrial activities presents a serious threat to environmental sustainability and ecological integrity. Bioremediation has gained immense interest around the world due to its environmentally friendly and cost-effective nature. In contrast to physical and chemical methods, the use of microbial enzymes, particularly immobilized biocatalysts, has been demonstrated as a versatile approach for the sustainable mitigation of environmental pollution. Considerable attention is now devoted to developing novel enzyme engineering approaches and state-of-the-art bioreactor design for ameliorating the overall bio-catalysis and biodegradation performance of enzymes. This review discusses the contemporary and state of the art technical and scientific progress regarding applying oxidoreductase enzymebased biocatalytic systems to remediate a vast number of pharmaceutically active compounds from water and wastewater bodies. A comprehensive insight into enzyme immobilization, the role of mediators, bioreactors designing, and transformation products of pharmaceuticals and their associated toxicity is provided. Additional studies are necessary to elucidate enzymatic degradation mechanisms, monitor the toxicity levels of the resulting degraded metabolites and optimize the entire bio-treatment strategy for technical and economical affordability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据